Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Multiple Sclerosis, Relapsing-Remitting Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

5 recruiting trials for Multiple Sclerosis, Relapsing-Remitting. Eligibility criteria explained in plain English.

TrialFinderData lists 5 Multiple Sclerosis, Relapsing-Remitting clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Research is led by IRCCS National Neurological Institute "C. Mondino" Foundation (1), Shirley Ryan AbilityLab (1), Medical University of Vienna (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is Mediterranean Diet (dietary_supplement, 1 trial), followed by Ketogenic Diet, Control group.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
5
Total Trials
5
Recruiting Now
0
Phase 3 Trials
5
Sponsors

Track Multiple Sclerosis, Relapsing-Remitting trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT06715436

Multiple Sclerosis and the Effects of Ketogenic Diet Therapy

Multiple sclerosis (MS) is an inflammatory and immune-mediated neurological disease with multifactorial etiology. The specific etiopathogenetic mechanisms of MS are still unknown...

Sponsor: IRCCS National Neurological Institute "C. Mondino" FoundationEnrolling: 1111 location
RECRUITINGNCT06276634

Intermittent Hypoxia in Persons With Multiple Sclerosis

This study aims to understand the mechanisms of a novel intervention involving breathing short durations of low levels of oxygen for persons with multiple sclerosis (MS). This...

Sponsor: Shirley Ryan AbilityLabEnrolling: 211 location
RECRUITINGNCT03401879

Retinal Neuro-vascular Coupling in Patients With Multiple Sclerosis

Multiple sclerosis (MS) affects approximately 2.3 million patients worldwide, with a global median prevalence of 33 per 100,000. MS is diagnosed at an average of 30 years and...

Sponsor: Medical University of ViennaEnrolling: 501 location
RECRUITINGNCT06919900

Motor Learning of Fall Resistant Skills Through Slip and Trip Exposure in Multiple Sclerosis

The primary purpose of this interventional study is to examine the overall motor learning capacity from exposure to repeated perturbations among ambulatory people with multiple...

Sponsor: Georgia State UniversityEnrolling: 641 location
RECRUITINGNCT06389968

Light Stimulation to Improve Visual Function After Optic Neuritis in Persons with Multiple Sclerosis

The aim of this monocentric randomized controlled intervention study is to improve visual function in persons with multiple sclerosis following optic neuritis (neuritis nervi...

Sponsor: Technical University of MunichEnrolling: 501 location

Frequently Asked Questions

There are currently 5 clinical trials for Multiple Sclerosis, Relapsing-Remitting, with 5 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Multiple Sclerosis, Relapsing-Remitting, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Multiple Sclerosis, Relapsing-Remitting, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.